Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 524-531

  Cortes, Jorge ^a   Hochhaus, Andreas ^a   Hughes, Timothy ^a   Kantarjian, Hagop ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AP 24534; BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DANUSERTIB; DASATINIB; DCC 2036; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; XL 228;

CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHROMOSOME ABERRATIONS; DNA MISMATCH REPAIR; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SALVAGE THERAPY;

EID: 79952081141     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.3619     Document Type: Review

References (77)

1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1501, 1960
2. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293, 1973
3. Bartram CR, de Klein A, Hagemeijer A, et al: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-280, 1983 (Pubitemid 14232360)
4. Anafi M, Gazit A, Gilon C, et al: Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem 267:4518-4523, 1992
5. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830, 1990
6. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
7. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
8. Deininger M, O'Brien S G, Guilhot F, et al: International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114, 2009 (abstr 1126)
9. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001 (Pubitemid 32743979)
10. Hochhaus A, Baccarani M, Deininger M, et al: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200-1206, 2008 (Pubitemid 351833788)
11. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006 (Pubitemid 43882349)
12. Shah NP, Kim DW, Kantarjian H, et al: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232-240, 2010
13. Kantarjian H, Giles F, Bhalla K, et al: Update On imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes. Blood 114, 2009 (abstr 1129)
14. Cortes J, Kantarjian H, Brummendorf TH, et al: Safety and efficacy of bosutinib (SKI-606) in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib. J Clin Oncol 28:487s, 2010 (abstr 6502)
15. Baccarani M, Cortes J, Pane F, et al: Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia-Net. J Clin Oncol 27:6041-6051, 2009
16. Kantarjian HM, O'Brien S, Cortes JE, et al: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent longterm prognosis. Cancer 97:1033-1041, 2003 (Pubitemid 36173155)
17. Hochhaus A, Reiter A, Saussele S, et al: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission - German CML Study Group and the UK MRC CML Study Group. Blood 95:62-66, 2000 (Pubitemid 30017225)
18. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
19. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
20. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An Analysis from the international randomized study of interferon versus STI571 (IRIS). Blood 2010 [epub ahead of print]
21. Press RD, Galderisi C, Yang R, et al: A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13:6136-6143, 2007 (Pubitemid 350075073)
22. Verma D, Kantarjian H, Shan J, et al: Sustained complete molecular response to imatinib in chronic myeloid leukemia: A target worth aiming and achieving? Blood 114:208, 2009 (abstr 505)
23. Mahon FX, Rea D, Guilhot F, et al: Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 114:353, 2009 (abstr 859)
24. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
25. Cortes JE, Baccarani M, Guilhot F, et al: Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424-430, 2010
26. Cortes JE, Jones D, O'Brien S, et al: Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28: 398-404, 2010
27. Cortes JE, Jones D, O'Brien S, et al: Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392-397, 2010
28. Rosti G, Palandri F, Castagnetti F, et al: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114:4933-4938, 2009
29. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
30. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
31. Castagnetti F, Palandri F, Amabile M, et al: Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party. Blood 113:3428-3434, 2009
32. Cortes JE, Kantarjian HM, Goldberg SL, et al: High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754-4759, 2009
33. Hughes TP, Branford S, White DL, et al: Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112:3965-3973, 2008
34. Kantarjian H, Talpaz M, O'Brien S, et al: Highdose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004 (Pubitemid 38451654)
35. Baccarani M, Rosti G, Castagnetti F, et al: Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: A European LeukemiaNet Study. Blood 113:4497-4504, 2009
36. Baccarani M, Druker B, Cortes J, et al: 24 Months update of the TOPS study: A phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase. Blood 114, 2009 (abstr 337)
37. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al: Randomized comparison of imatinib 800 mg vs. imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: Analysis of molecular remission at 12 months - The German CML-Study IV. Blood 114, 2009 (abstr 339)
38. White DL, Dang P, Engler J, et al: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761-2767, 2010
39. Cortes J, Quintás-Cardama A, Jones D, et al: Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated-interferonalfa-2b and GM-CSF. Cancer 10.1002/cncr.25438 [epub ahead of print on September 30, 2010]
40. Guilhot F, Preudhomme C, Guilhot J, et al: Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib for the treatment of newly diagnosed chronic phase chronic myeloid leukaemia patients: Confirmatory results at 18 months of part 1 of the Spirit phase iii randomized trial of the French CML group (FI LMC). Blood 114, 2009 (abstr 340)
41. Baccarani M, Martinelli G, Rosti G, et al: Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245-4251, 2004 (Pubitemid 39620179)
42. Bradeen HA, Eide CA, O'Hare T, et al: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 108:2332-2338, 2006 (Pubitemid 44497517)
43. Al-Kali A, Kantarjian H, Shan J, et al: Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 2010 [epub ahead of print]
44. Guilhot F, Larson R, O'Brien S: Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood 110, 2007 (abstr 27)
45. Quintás-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 2009
46. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
47. Lucas CM, Wang L, Austin GM, et al: A population study of imatinib in chronic myeloid leukemia demonstrates lower efficacy than in clinical trials. Leukemia 22:1963-1966, 2008
48. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007 (Pubitemid 46053043)
49. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204-2205, 2004 (Pubitemid 39297882)
50. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28:S71-S73, 2004 (suppl) (Pubitemid 38251502)
51. Bocchia M, Gentili S, Abruzzese E, et al: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 365:657-662, 2005 (Pubitemid 40260886)
52. Jain N, Reuben JM, Kantarjian H, et al: Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: A phase 2 trial. Cancer 115:3924-3934, 2009
53. Rojas JM, Knight K, Wang L, et al: Clinical evaluation of BCR-ABL peptide immunization in chronic myeloid leukemia: Results of the EPIC study. Leukemia 21:2287-2295, 2007 (Pubitemid 350011701)
54. Bocchia M, Defina M, Ippoliti M, et al: BCRABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: Interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. Blood 114, 2009 (abstr 648)
55. Qazilbash MH, Wieder E, Rios R, et al: Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 104:77a, 2004 (abstr 259)
56. Li Z, Qiao Y, Liu B, et al: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11:4460-4468, 2005 (Pubitemid 40825636)
57. Smith BD, Kasamon YL, Kowalski J, et al: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 16:338-347, 2010
58. Burchert A, Müller MC, Kostrewa P, et al: Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28:1429-1435, 2010
59. Dierks C, Beigi R, Guo GR, et al: Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14: 238-249, 2008
60. Baccarani M, Rosti G, Saglio G, et al: Dasatinib time to and durability of major and complete cytogenetic response in patients with chronic myeloid leukemia in chronic phase. Blood 112, 2008 (abstr 450)
61. Cortes J, Kantarjian H, Kim DW, et al: Efficacy and safety of bosutinib (SKI-606) in patients with chronic-phase Ph+ chronic myelogenous leukemia with resistance or intolerance to imatinib. Blood 112, 2008 (abstr 1098)
62. Quintás-Cardama A, Cortes JE, O'Brien S, et al: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:2912-2921, 2009
63. Alvarado Y, Kantarjian H, O'Brien S, et al: Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the longterm outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115:3709-3718, 2009
64. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444, 2008
65. O'Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505, 2005
66. Redaelli S, Piazza R, Rostagno R, et al: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469-471, 2009
67. Müller MC, Cortes JE, Kim DW, et al: Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944-4953, 2009
68. Hughes T, Saglio G, Branford S, et al: Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27:4204-4210, 2009
69. Jabbour E, Jones D, Kantarjian HM, et al: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114:2037-2043, 2009
70. Quintás-Cardama A, Kantarjian H, O'brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007 (Pubitemid 47477268)
71. Quintás-Cardama A, Kantarjian H, Ravandi F, et al: Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115: 2482-2490, 2009
72. Quintás-Cardama A, Han X, Kantarjian H, et al: Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114:261-263, 2009
73. Garg RJ, Kantarjian H, O'Brien S, et al: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood 114:4361-4368, 2009
74. Jabbour E, Kantarjian H, Jones D, et al: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112:53-55, 2008
75. Nicolini FE, Mauro MJ, Martinelli G, et al: Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 114: 5271-5278, 2009
76. Velev N, Cortes J, Champlin R, et al: Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116:3631-3637
77. Nicolini FE, Zhou W, Martinelli G, et al: Impact of allogeneic stem cell transplantation as salvage therapy after T315I mutation detection in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients. Blood 114, 2009 (abstr 645)